|

AdHER2DC vaccine Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Carcinoma of Endometrium1
  • Cancer of Endometrium1
  • Endometrial Carcinoma1
  • Endometrial Cancer1
  • Cancer1

Bethesda, Maryland1 trial

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.